Concepts (169)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Inflammatory Breast Neoplasms | 7 | 2020 | 150 | 1.140 |
Why?
|
| Breast Neoplasms | 34 | 2024 | 21206 | 0.990 |
Why?
|
| Mammography | 21 | 2024 | 2433 | 0.870 |
Why?
|
| Ultrasonography, Mammary | 7 | 2015 | 243 | 0.610 |
Why?
|
| Mastectomy, Segmental | 1 | 2022 | 974 | 0.560 |
Why?
|
| Breast | 13 | 2024 | 1976 | 0.510 |
Why?
|
| Patient Positioning | 1 | 2014 | 332 | 0.370 |
Why?
|
| Magnetic Resonance Imaging | 14 | 2024 | 36742 | 0.320 |
Why?
|
| Image Enhancement | 4 | 2014 | 2880 | 0.320 |
Why?
|
| Carcinoma, Lobular | 2 | 2020 | 480 | 0.280 |
Why?
|
| Carcinoma, Ductal, Breast | 4 | 2020 | 1099 | 0.270 |
Why?
|
| Artifacts | 1 | 2014 | 1923 | 0.240 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 3 | 2011 | 934 | 0.220 |
Why?
|
| Phyllodes Tumor | 1 | 2003 | 55 | 0.220 |
Why?
|
| Patient Care Team | 1 | 2013 | 2521 | 0.200 |
Why?
|
| Breast Diseases | 4 | 2024 | 442 | 0.190 |
Why?
|
| Wireless Technology | 1 | 2022 | 102 | 0.190 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2020 | 2054 | 0.180 |
Why?
|
| Papilloma, Intraductal | 1 | 1999 | 21 | 0.170 |
Why?
|
| Palpation | 3 | 2005 | 166 | 0.160 |
Why?
|
| Mammaplasty | 3 | 2019 | 1268 | 0.160 |
Why?
|
| Iodine Radioisotopes | 1 | 2022 | 1034 | 0.160 |
Why?
|
| Early Detection of Cancer | 5 | 2023 | 3237 | 0.150 |
Why?
|
| Gadolinium | 1 | 2003 | 964 | 0.150 |
Why?
|
| Sensitivity and Specificity | 8 | 2014 | 14718 | 0.140 |
Why?
|
| Mass Screening | 5 | 2023 | 5458 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2020 | 9412 | 0.130 |
Why?
|
| Neoadjuvant Therapy | 5 | 2018 | 2902 | 0.130 |
Why?
|
| Female | 40 | 2024 | 397113 | 0.130 |
Why?
|
| Chemotherapy, Adjuvant | 7 | 2018 | 3553 | 0.120 |
Why?
|
| Carcinoma | 2 | 2017 | 2330 | 0.120 |
Why?
|
| Patient Care Planning | 1 | 2020 | 905 | 0.120 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2003 | 3780 | 0.110 |
Why?
|
| Radiopharmaceuticals | 2 | 2020 | 2736 | 0.100 |
Why?
|
| Diagnosis, Differential | 5 | 2020 | 13000 | 0.100 |
Why?
|
| Humans | 45 | 2024 | 767991 | 0.090 |
Why?
|
| Echo-Planar Imaging | 3 | 2005 | 648 | 0.090 |
Why?
|
| Equipment Failure Analysis | 1 | 2014 | 845 | 0.090 |
Why?
|
| Receptor, erbB-2 | 5 | 2020 | 2601 | 0.090 |
Why?
|
| Lactation | 2 | 2023 | 392 | 0.090 |
Why?
|
| B-Lymphocytes | 1 | 2024 | 4791 | 0.090 |
Why?
|
| Neovascularization, Pathologic | 2 | 2015 | 2630 | 0.090 |
Why?
|
| Middle Aged | 27 | 2024 | 223422 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2017 | 11873 | 0.080 |
Why?
|
| Adult | 28 | 2024 | 223583 | 0.080 |
Why?
|
| Aged | 22 | 2024 | 171446 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 2 | 2011 | 3618 | 0.080 |
Why?
|
| Receptors, Progesterone | 3 | 2020 | 1160 | 0.080 |
Why?
|
| Reproducibility of Results | 6 | 2015 | 20218 | 0.070 |
Why?
|
| Contrast Media | 3 | 2014 | 5330 | 0.070 |
Why?
|
| Rectus Abdominis | 1 | 2008 | 101 | 0.070 |
Why?
|
| Risk Factors | 6 | 2023 | 74936 | 0.070 |
Why?
|
| Diagnostic Errors | 1 | 2014 | 1280 | 0.070 |
Why?
|
| T-Lymphocytes | 1 | 2024 | 10264 | 0.070 |
Why?
|
| Mastectomy, Modified Radical | 2 | 2017 | 62 | 0.070 |
Why?
|
| Breast Implants | 1 | 2010 | 414 | 0.070 |
Why?
|
| Equipment Design | 1 | 2014 | 3522 | 0.060 |
Why?
|
| Education, Medical, Graduate | 1 | 2018 | 2420 | 0.060 |
Why?
|
| Radiographic Image Enhancement | 2 | 2021 | 877 | 0.060 |
Why?
|
| Gadolinium DTPA | 2 | 2005 | 823 | 0.060 |
Why?
|
| Biopsy | 3 | 2024 | 6786 | 0.060 |
Why?
|
| Retrospective Studies | 14 | 2022 | 81746 | 0.060 |
Why?
|
| Radiology | 1 | 2018 | 2104 | 0.060 |
Why?
|
| Radiotherapy | 1 | 2011 | 1501 | 0.060 |
Why?
|
| Patient Compliance | 1 | 2014 | 2697 | 0.050 |
Why?
|
| Mastectomy | 3 | 2019 | 1861 | 0.050 |
Why?
|
| Sclerosis | 1 | 2024 | 211 | 0.050 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2004 | 131 | 0.050 |
Why?
|
| Quality Improvement | 1 | 2018 | 3855 | 0.050 |
Why?
|
| Aged, 80 and over | 8 | 2017 | 59598 | 0.050 |
Why?
|
| Hamartoma | 1 | 2004 | 236 | 0.050 |
Why?
|
| Neoplasm Staging | 4 | 2020 | 11221 | 0.050 |
Why?
|
| Menstrual Cycle | 1 | 2005 | 546 | 0.050 |
Why?
|
| Ki-67 Antigen | 1 | 2003 | 630 | 0.050 |
Why?
|
| Femur Head | 1 | 2003 | 297 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2017 | 1788 | 0.040 |
Why?
|
| Progesterone | 1 | 2005 | 752 | 0.040 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2007 | 1232 | 0.040 |
Why?
|
| Receptors, Estrogen | 2 | 2020 | 2253 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2011 | 4904 | 0.040 |
Why?
|
| Physical Examination | 2 | 2003 | 1263 | 0.040 |
Why?
|
| Surgical Flaps | 1 | 2008 | 1682 | 0.040 |
Why?
|
| Cartilage | 1 | 2003 | 811 | 0.040 |
Why?
|
| Tamoxifen | 1 | 2004 | 966 | 0.040 |
Why?
|
| BRCA2 Protein | 1 | 2024 | 802 | 0.040 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2005 | 1209 | 0.040 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2002 | 594 | 0.040 |
Why?
|
| Internship and Residency | 1 | 2018 | 5952 | 0.040 |
Why?
|
| Lymphatic Metastasis | 2 | 2015 | 2908 | 0.040 |
Why?
|
| BRCA1 Protein | 1 | 2024 | 1155 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 20757 | 0.030 |
Why?
|
| Axilla | 1 | 2018 | 623 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2024 | 18062 | 0.030 |
Why?
|
| Cysts | 1 | 2001 | 685 | 0.030 |
Why?
|
| Breast Feeding | 1 | 2023 | 1363 | 0.030 |
Why?
|
| Anthracyclines | 1 | 2017 | 286 | 0.030 |
Why?
|
| False Negative Reactions | 2 | 2007 | 571 | 0.030 |
Why?
|
| Taxoids | 1 | 2017 | 665 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 9116 | 0.030 |
Why?
|
| Hormones | 1 | 2017 | 866 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 7445 | 0.030 |
Why?
|
| Calcinosis | 1 | 2001 | 1481 | 0.030 |
Why?
|
| Lymph Node Excision | 1 | 2018 | 1269 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2017 | 1014 | 0.020 |
Why?
|
| Survival Rate | 2 | 2017 | 12828 | 0.020 |
Why?
|
| Autoimmune Diseases | 1 | 2024 | 2256 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2005 | 6004 | 0.020 |
Why?
|
| Analysis of Variance | 3 | 2005 | 6228 | 0.020 |
Why?
|
| Biopsy, Needle | 2 | 2008 | 1622 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2017 | 2227 | 0.020 |
Why?
|
| Estrogen Receptor alpha | 1 | 2015 | 581 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2024 | 15442 | 0.020 |
Why?
|
| Models, Biological | 2 | 2003 | 9493 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2003 | 11068 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2015 | 1904 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2015 | 2660 | 0.020 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 39345 | 0.020 |
Why?
|
| Risk | 1 | 2018 | 9609 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2018 | 10098 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2008 | 1151 | 0.020 |
Why?
|
| Fibroadenoma | 1 | 2004 | 42 | 0.010 |
Why?
|
| Pregnancy | 2 | 2023 | 30260 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 6843 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 6517 | 0.010 |
Why?
|
| Extracellular Fluid | 1 | 2005 | 165 | 0.010 |
Why?
|
| Linear Models | 2 | 2005 | 5884 | 0.010 |
Why?
|
| Massachusetts | 2 | 2007 | 8888 | 0.010 |
Why?
|
| Prospective Studies | 2 | 2005 | 54924 | 0.010 |
Why?
|
| Stromal Cells | 1 | 2008 | 1336 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 12536 | 0.010 |
Why?
|
| Mathematics | 1 | 2003 | 704 | 0.010 |
Why?
|
| Observer Variation | 1 | 2007 | 2618 | 0.010 |
Why?
|
| Blood Volume | 1 | 2002 | 545 | 0.010 |
Why?
|
| Time Factors | 2 | 2017 | 40214 | 0.010 |
Why?
|
| Premenopause | 1 | 2004 | 1039 | 0.010 |
Why?
|
| Hormone Replacement Therapy | 1 | 2005 | 757 | 0.010 |
Why?
|
| Mutation | 1 | 2024 | 30211 | 0.010 |
Why?
|
| Age Distribution | 1 | 2004 | 2871 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 2002 | 1500 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 2005 | 1880 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2005 | 2234 | 0.010 |
Why?
|
| Decision Support Techniques | 1 | 2008 | 2008 | 0.010 |
Why?
|
| Prognosis | 1 | 2018 | 29979 | 0.010 |
Why?
|
| Disease Progression | 1 | 2015 | 13665 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2018 | 65364 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2005 | 1728 | 0.010 |
Why?
|
| Microcirculation | 1 | 2002 | 1281 | 0.010 |
Why?
|
| Posture | 1 | 2001 | 957 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 4857 | 0.010 |
Why?
|
| Menopause | 1 | 2005 | 1656 | 0.010 |
Why?
|
| Postmenopause | 1 | 2005 | 2518 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 4473 | 0.010 |
Why?
|
| Attitude to Health | 1 | 2004 | 2024 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 2003 | 1798 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2007 | 12464 | 0.010 |
Why?
|
| Algorithms | 1 | 2014 | 14163 | 0.010 |
Why?
|
| Artificial Intelligence | 1 | 2007 | 2665 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2003 | 8535 | 0.010 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2004 | 3231 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2003 | 4063 | 0.010 |
Why?
|
| United States | 1 | 2018 | 73027 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2003 | 8740 | 0.010 |
Why?
|
| Software | 1 | 2003 | 4478 | 0.000 |
Why?
|
| Calcium | 1 | 2001 | 5794 | 0.000 |
Why?
|
| Adolescent | 2 | 2007 | 89155 | 0.000 |
Why?
|
| Case-Control Studies | 1 | 2005 | 22287 | 0.000 |
Why?
|
| Young Adult | 1 | 2014 | 60048 | 0.000 |
Why?
|
| Age Factors | 1 | 2003 | 18407 | 0.000 |
Why?
|
| Male | 1 | 2008 | 364641 | 0.000 |
Why?
|
Concepts
(169)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(41)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_